Osteopore signed an exclusive option to license novel 3D-printed modular bone implant technology in development at the Queensland University of Technology (QUT). The technology complements Osteopore’s current bone regenerating products such as the Osteoplug™ (shown above) and Osteomesh™ resorbable implants, and has shown encouraging early stage results for regrowth of long bone defects in patients who have lost more than six centimeters of bone to injury or disease.
The modular device in development allows stacking and locking between implants while enabling the surgeon to customize the reconstruction of bone defects based on needs during a procedure.
QUT and Osteopore will initially collaborate to generate sufficient clinical data to support regulatory submissions to the TGA, FDA and European regulators, and de-risk the technology before evaluation of the potential for acquisition of the technology by Osteopore. If successful, Osteopore has the option to secure exclusive commercialization rights via a further licensing agreement.
Osteopore signed an exclusive option to license novel 3D-printed modular bone implant technology in development at the Queensland University of Technology (QUT). The technology complements Osteopore’s current bone regenerating products such as the Osteoplug™ (shown above) and Osteomesh™ resorbable implants, and has shown encouraging early...
Osteopore signed an exclusive option to license novel 3D-printed modular bone implant technology in development at the Queensland University of Technology (QUT). The technology complements Osteopore’s current bone regenerating products such as the Osteoplug™ (shown above) and Osteomesh™ resorbable implants, and has shown encouraging early stage results for regrowth of long bone defects in patients who have lost more than six centimeters of bone to injury or disease.
The modular device in development allows stacking and locking between implants while enabling the surgeon to customize the reconstruction of bone defects based on needs during a procedure.
QUT and Osteopore will initially collaborate to generate sufficient clinical data to support regulatory submissions to the TGA, FDA and European regulators, and de-risk the technology before evaluation of the potential for acquisition of the technology by Osteopore. If successful, Osteopore has the option to secure exclusive commercialization rights via a further licensing agreement.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
